Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05426005 | Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 28 | Sun Yat-sen UniversityOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT05497778 | A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer. | active not recruiting | Phase 1 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT03697408 | Itacitinib + Everolimus in Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 23 | University of PennsylvaniaOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03709758 | Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML | active not recruiting | Phase 1 | 50 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03872947 | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 138 | Toray Industries, IncINDUSTRY | 2 | Jun 23, 2026 | clinicaltrials |
| NCT03991819 | Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer(BiniPembro) | active not recruiting | Phase 1 | 40 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04536805 | Relapse in Previously Irradiated Prostate Bed : Stereotactic Ablative Reirradiation Potentiated by Metformin(REPAIR) | active not recruiting | Phase 1 / Phase 2 | 44 | Institut Cancerologie de l'OuestOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03277729 | A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas | active not recruiting | Phase 1 / Phase 2 | 53 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT03476681 | Study of NEO-201 in Solid Tumors Expansion Cohorts | active not recruiting | Phase 1 / Phase 2 | 121 | Precision Biologics, IncINDUSTRY | 1 | Jun 22, 2026 | clinicaltrials |
| NCT04188548 | A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer(EMBER) | active not recruiting | Phase 1 | 379 | Eli Lilly and CompanyINDUSTRY | 8 | Jun 22, 2026 | clinicaltrials |
| NCT04555551 | MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma | active not recruiting | Phase 1 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT04857372 | A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors | active not recruiting | Phase 1 | 137 | Novartis PharmaceuticalsINDUSTRY | 11 | Jun 22, 2026 | clinicaltrials |
| NCT05143970 | A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors(CHANCES) | active not recruiting | Phase 1 | 27 | Institut Paoli-CalmettesOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT05180695 | HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas(AMPHISARC) | active not recruiting | Phase 1 / Phase 2 | 47 | Centre Leon BerardOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT05455697 | Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma | active not recruiting | Phase 1 / Phase 2 | 33 | University of WashingtonOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT03299309 | PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma(PRiME) | active not recruiting | Phase 1 | 30 | Daniel LandiOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT04503278 | A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors | active not recruiting | Phase 1 | 214 | BioNTech Cell & Gene Therapies GmbHINDUSTRY | 4 | Jun 18, 2026 | clinicaltrials |
| NCT04616248 | In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors | active not recruiting | Phase 1 | 14 | University of Southern CaliforniaOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06257264 | A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors | active not recruiting | Phase 1 | 103 | BeiGeneINDUSTRY | 6 | Jun 18, 2026 | clinicaltrials |
| NCT02862275 | Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer | active not recruiting | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT03362060 | PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer | active not recruiting | Phase 1 | 20 | Massachusetts General HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT03945721 | A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients(UNITY) | active not recruiting | Phase 1 | 21 | Massachusetts General HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT04036682 | A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer(REZILIENT1) | active not recruiting | Phase 1 / Phase 2 | 284 | Cullinan Therapeutics Inc.INDUSTRY | 9 | Jun 17, 2026 | clinicaltrials |
| NCT04160494 | D2C7-IT With Atezolizumab for Recurrent Gliomas | active not recruiting | Phase 1 | 18 | Darell BignerOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT04317105 | Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN | active not recruiting | Phase 1 / Phase 2 | 54 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT04533750 | Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin | active not recruiting | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2026 | clinicaltrials |
| NCT04906902 | Acalabrutinib in CNSL | active not recruiting | Phase 1 / Phase 2 | 49 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT05934838 | A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas | active not recruiting | Phase 1 | 15 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT06318273 | A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 1 | 152 | AbbVieINDUSTRY | 7 | Jun 17, 2026 | clinicaltrials |
| NCT03657641 | Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 73 | University of Southern CaliforniaOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT03690011 | Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells | active not recruiting | Phase 1 | 45 | Baylor College of MedicineOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT04796220 | Focused Ultrasound and Gemcitabine in Breast Cancer(Breast 54) | active not recruiting | Phase 1 | 32 | Patrick Dillon, MDOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06390995 | A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 28 | TakedaINDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07150091 | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM | active not recruiting | Phase 1 / Phase 2 | 20 | GlaxoSmithKlineINDUSTRY | 8 | Jun 16, 2026 | clinicaltrials |
| NCT02427451 | Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia | active not recruiting | Phase 1 / Phase 2 | 87 | Kerry RogersOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT02671435 | A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 383 | MedImmune LLCINDUSTRY | 11 | Jun 15, 2026 | clinicaltrials |
| NCT04323046 | Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults | active not recruiting | Phase 1 | 9 | Sabine Mueller, MD, PhDOTHER | 2 | Jun 15, 2026 | clinicaltrials |
| NCT05358249 | Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation(KontRASt-03) | active not recruiting | Phase 1 / Phase 2 | 74 | Novartis PharmaceuticalsINDUSTRY | 8 | Jun 15, 2026 | clinicaltrials |
| NCT06104488 | A Study of Avutometinib for People With Solid Tumor Cancers | active not recruiting | Phase 1 | 3 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT01192555 | Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma(ATOMIC) | active not recruiting | Phase 1 / Phase 2 | 11 | Baylor College of MedicineOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT01430390 | In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies | active not recruiting | Phase 1 | 19 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03162536 | A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | active not recruiting | Phase 1 / Phase 2 | 190 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03602157 | Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL | active not recruiting | Phase 1 | 43 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04616183 | LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 46 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05075993 | Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors | active not recruiting | Phase 1 | 352 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05327270 | Non-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignant Lesions | active not recruiting | Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05563220 | Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer(ELEVATE) | active not recruiting | Phase 1 / Phase 2 | 435 | Stemline Therapeutics, Inc.INDUSTRY | 13 | Jun 12, 2026 | clinicaltrials |
| NCT02503722 | Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer | active not recruiting | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 2 | Jun 11, 2026 | clinicaltrials |
| NCT02726997 | Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur) | active not recruiting | Phase 1 / Phase 2 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT03041688 | Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia | active not recruiting | Phase 1 | 58 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Jun 24, 2026source: clinicaltrials